Bellvitge leads the creation of a new, more precise tool to assess chemotherapy-induced neurological toxicity
IDIBELL, HUB and ICO have led a European study that presents an innovative tool to assess chemotherapy-induced peripheral neuropathy (CIPN). The great advantage of this system is that it incorporates the patient’s perception, an aspect that until now medical scales did not adequately take into account.